CoChat

Enduring sexual dysfunction after treatment with antidepressants, 5 α -reductase inhibitors and isotretinoin: 300 cases

Open access
Healy, David, Le Noury, Joanna, Mangin, Derelie · 2018 · International Journal of Risk & Safety in Medicine

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: To investigate clinical reports of post-SSRI sexual dysfunction (PSSD), post-finasteride syndrome (PFS) and enduring sexual dysfunction following isotretinoin. METHODS: Data from RxISK.org, a global adverse event reporting website, have been used to establish the clinical features, demographic details and clinical trajectories of syndromes of persistent sexual difficulties following three superficially different treatment modalities. RESULTS: We report on 300 cases of enduring sexual dysfunction from 37 countries following 14 different drugs comprised of serotonin reuptake inhibiting antidepressants, 5 α-reductase inhibitors and isotretinoin. While reports of certain issues were unique to the antidepressants, such as the onset of premature ejaculation and persistent genital arousal disorder (PGAD), there was also a significant overlap in symptom profile between the drug groups, with common features including genital anaesthesia, pleasureless or weak orgasm, loss of libido and impotence. Secondary consequences included relationship breakdown and impaired quality of life. CONCLUSIONS: These data point to a legacy syndrome or syndromes comprising a range of disturbances to sexual function. More detailed studies will require developments in coding systems that recognise the condition(s). Further exploration of these tardive sexual syndromes may yield greater understanding of tardive syndromes in general.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3233/jrs-180744

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

2 retracted

Research works printed but not linked: 2

  1. Bahrick AS, 2006, American Society for the Advancement of Pharmacotherapy Tablet, 7, 2
  2. Montejo AL, 1999, Actas Esp Psiquiatr, 27, 23

Cited by

See all 86

Metadata

Authors
Healy, D., Le Noury, J., & Mangin, D.
Affiliations
  • Bangor University (GB)
  • North Wales Department of Psychological Medicine, Bangor, Wales, UK
  • David Braley and Nancy Gordon Chair of Family Medicine, Department of Family Medicine, McMaster University, ON, Canada
Corresponding author
Healy, David
Venue
International Journal of Risk & Safety in Medicine
Published
2018-08
Volume
29
Issue
3-4
Pages
125-134
ISSN
  • 0924-6479 (ISSN-L)
  • 1878-6847
OpenAlex
W2802435708
Cited by
81
References
34
Citations by year
2026: 6 · 2025: 6 · 2024: 8 · 2023: 9 · 2022: 12 · 2021: 10 · 2020: 13 · 2019: 13 · 2018: 3
FWCI
7.62
Type
journal article
Language
en
Open access
Locations
  • International Journal of Risk & Safety in Medicine (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Sexual function and dysfunction studies
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Keywords
sexual dysfunction, antidepressants, selective serotonin reuptake inhibitors, finasteride, 5-alpha reductase inhibitors, isotretinoin, adverse drug reactions, premature ejaculation, persistent genital arousal disorder, low libido, erectile dysfunction, tardive syndromes, adverse event reporting
MeSH terms
Adolescent, Adult, Aged, Antidepressive Agents, Dermatologic Agents, Female, Humans, Libido, Male, Middle Aged, Product Surveillance, Postmarketing, Quality of Life, Sexual Dysfunction, Physiological, Isotretinoin, Young Adult, 5-alpha Reductase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.